Login / Signup

Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.

Auke T BergemanKrystien V V LieveDania KallasJ Martijn BosFerran Roses Y NoguerIsabelle DenjoyEsther Zorio-GrimaJanneke A E KammeraadPuck J PeltenburgKathryn E TobertTakeshi AibaJoseph AtallahFabrizio DragoAnjan S BatraRamón BrugadaMartin BorggrefeSally-Ann B ClurMoniek G P J CoxAndrew M DavisSantokh S DhillonSusan P EtheridgePeter FischbachSonia FranciosiKristina Hermann HaugaaMinoru HorieChristopher JohnsrudeAustin M KaneUlrich KrauseSit-Yee KwokMartin J LaPageSeiko OhnoVincent ProbstJason D RobertsTomas RobynsFrédéric SacherChristopher SemsarianJonathan R SkinnerHeikki SwanTerezia TavacovaSvjetlana Tisma-DupanovicJacob Tfelt HansenSing-Chien YapPrince J KannankerilAntoine LeenhardtJanice TillShubhayan SanataniMichael W T TanckMichael J AckermanArthur A M WildeChristian van der Werf
Published in: Circulation (2023)
For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.
Keyphrases
  • end stage renal disease
  • risk factors
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • stem cells
  • angiotensin converting enzyme
  • mesenchymal stem cells
  • bone marrow
  • replacement therapy
  • chemotherapy induced